Drilldown: Medicines
Medicines > onset 
:
Over weeks or
Symptomatic effect within weeks; full response by 12-24 weeks or
~30 min
:
Over weeks or
Symptomatic effect within weeks; full response by 12-24 weeks or
~30 min Use the filters below to narrow your results.
generic:
brand:
classes:
Anti-CGRP ligand monoclonal antibody (2) ·
Dual orexin receptor antagonist (DORA) (3) ·
PDE5 Inhibitor (1) ·
the first approved (1) ·
[[:Category:Biologics|Biologic]] (1) ·
[[:Category:DMARDs|DMARD]] (1) ·
[[:Category:Immunosuppressants|Immunosuppressant]] (1) ·
[[:Category:Monoclonal_antibodies|Monoclonal antibody (fully human IgG1)]] (1) ·
[[:Category:TNF_inhibitors|TNF-α inhibitor]] (1)
mechanism:
None (1) ·
Competitive antagonist at OX1R and OX2R. Faster receptor association/dissociation kinetics than suvorexant (~16 sec dissociation vs ~57 sec) hypothesized to support sleep onset, with sufficient duration for maintenance. (1) ·
Competitive antagonist at OX1R and OX2R. First-in-class DORA. Receptor dissociation slower than lemborexant or daridorexant. (1) ·
Humanized IgG2 monoclonal antibody binding both isoforms of CGRP peptide (1) ·
Humanized IgG4 monoclonal antibody binding CGRP peptide; prevents CGRP from activating its receptor (1) ·
Selective inhibitor of PDE5. Slightly higher PDE5/PDE6 selectivity vs sildenafil (less visual side effect) but more PDE1 cross-activity (occasional QT effects at high doses). (1) ·
'"`UNIQ--vote-000010F8-QINU`"' Pre-treatment screening for latent TB (PPD or IGRA) and chronic hepatitis B is standard. Anti-drug antibody formation is a recognized cause of secondary loss of response'"`UNIQ--ref-000010F9-QINU`"'. (1)
uses:
None (1) ·
Insomnia (sleep onset and/or maintenance) in adults (FDA-approved August 2014). Also studied for insomnia in mild-moderate Alzheimer disease. (1) ·
Insomnia (sleep onset and/or maintenance) in adults (FDA-approved Dec 2019) (1) ·
Insomnia (sleep onset and/or sleep maintenance) in adults (FDA-approved Jan 2022) (1) ·
Preventive treatment of migraine in adults (episodic and chronic) (1) ·
Preventive treatment of migraine in adults; episodic cluster headache (1) ·
'"`UNIQ--vote-00000669-QINU`"' (1)
starting dose:
10 mg PO 30 min before bedtime (with ≥7 hours of sleep planned) (1) ·
10 mg ~1 h before sexual activity (1) ·
225 mg SC monthly, or 675 mg SC every 3 months (quarterly) (1) ·
25 mg PO at bedtime (no titration); may increase to 50 mg if 25 mg inadequate (1) ·
40 mg SC every other week (most adult indications); IBD induction 160 mg week 0, 80 mg week 2, then 40 mg every other week (1) ·
5 mg PO at bedtime; may increase to 10 mg if inadequate (1) ·
Migraine: 240 mg SC loading dose, then 120 mg SC monthly. Cluster: 300 mg SC at onset of cluster period, then monthly during cluster. (1)
preparations:
120 mg/mL prefilled syringe or autoinjector (1) ·
2.5, 5, 10, 20 mg tabs (Levitra); 10 mg ODT (Staxyn) (1) ·
225 mg/1.5 mL prefilled syringe or autoinjector (1) ·
25 mg, 50 mg tablets (1) ·
40 mg/0.4 mL or 40 mg/0.8 mL prefilled syringe and autoinjector pen; 10, 20, 80 mg pediatric/induction strengths (1) ·
5 mg, 10 mg tablets (1) ·
5 mg, 10 mg, 15 mg, 20 mg tablets (1)
fda max:
routes:
onset: (Click arrow to add another value)
duration:
halflife:
bioavailability:
pregnancy:
legal:
Showing below up to 7 results in range #1 to #7.